- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
-
ESG profile
- Media
- Partners
- Contact Us
Press Releases
Dec
- Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics announce the filing of an application for REEQONUS™ (favipiravir) Tablets for the treatment of COVID-19 under Health Canada’s Interim Order
- Secondary Listing of Dr. Reddy’s ADRs on NSE IFSC Limited (GIFT City, Gujarat, India)
- Dr. Reddy's and RDIF commence clinical trials for Sputnik V vaccine in India
Nov
- Dr. Reddy’s to acquire select Anti-Allergy brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan
- Dr. Reddy's Laboratories announces the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) in the U.S. Market
- Dr. Reddy’s Laboratories presents preclinical data at SITC 2020 demonstrating significant improvement in tumor growth inhibition and overall survival through a combination of E7777 (denileukin diftitox) and an immune checkpoint inhibitor
Oct
- Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India
- Dr. Reddy’s Q2 & H1 FY21 Financial Results
- Dr. Reddy's Laboratories announces appointment of new Chief Financial Officer
- Dr. Reddy’s announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market
- Dr. Reddy’s announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market
- Dr. Reddy’s and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India
- Dr. Reddy’s Laboratories joins Science Based Targets initiative (SBTi) and sets 2030 GHG emission targets
- Dr. Reddy's Laboratories announces the launch of a generic version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Cinacalcet Tablets in the U.S. Market
Sep
- Dr. Reddy's Laboratories announces the launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market
- Dr. Reddy's announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market
- Dr. Reddy’s announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. Market
- Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company
- RDIF and Dr. Reddy’s to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India
- Dr. Reddy's Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Redyx in India
- Dr. Reddy's Laboratories announces the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market
Aug
- Dr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market
- Dr. Reddy’s Laboratories enters hospital nutrition segment with Celevida Maxx in India
- Dr. Reddy's Laboratories announces the launch of AVIGAN® (Favipiravir) in India
- Dr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the U.S. Market
Jul
- Dr. Reddy’s Q1 FY21 Financial Results
- Dr. Reddy's Laboratories received approval of XEGLYZE™ (abametapir) lotion, 0.74%, in the U.S.
- Dr. Reddy's Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market
- Dr. Reddy’s partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a potential treatment of COVID-19
Jun
- Dr. Reddy's Laboratories to present at the Barclays Spec Pharma Fireside Chat Series
- Dr. Reddy's Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market
- Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F
- Dr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir
- Dr. Reddy's Laboratories announces the launch of ColchicineTablets USP, 0.6 mg in the U.S. Market
- Dr. Reddy’s Laboratories completes the acquisition of select business divisions of Wockhardt
May
- Dr. Reddy’s Q4 & FY20 Financial Results
- Dr. Reddy’s Laboratories announces the launch of FXR™ (obeticholic acid) in India
- Dr. Reddy's Laboratories announces the launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market
- Dr. Reddy's Laboratories received approval for their NDA, ELYXYB™ (celecoxib oral solution) 25 mg/mL, in the U.S.
Apr
- Dr. Reddy's Laboratories announces the launch of Fenofibrate Tablets USP, in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Amphetamine Sulfate Tablets USP, in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of an authorized generic version of NitroDur® (nitroglycerin) Transdermal Infusion System in the U.S. Market
- Dr. Reddy’s Laboratories announces the launch of Invista® (dasatinib) in India
Mar
- Dr. Reddy's Laboratories Issues Voluntary Nationwide Recall of Phytonadione Injectable Emulsion USP, 10 mg/mL Single-Dose Ampules Due To Ampules Breaking And Shattering Upon Opening
- Dr. Reddy's Laboratories announces the launch of Pyrimethamine Tablets USP, 25 mg, first-wave generic version of Daraprim® in the U.S. Market
- Dr. Reddy's Laboratories announces first-to-market launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market
Feb
- Dr. Reddy's Laboratories announces the first generic launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market
- Dr. Reddy’s Laboratories to acquire select business divisions of Wockhardt in India
- Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170
- Dr. Reddy's Laboratories announces the launch of Trientine Hydrochloride Capsules USP, 250 mg, in the U.S. Market
